KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Tax Provisions (2018 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Tax Provisions for 8 consecutive years, with $538000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Tax Provisions rose 113.98% to $538000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 million, a 124.85% increase, with the full-year FY2025 number at $1.0 million, up 124.85% from a year prior.
  • Tax Provisions was $538000.0 for Q4 2025 at Xenon Pharmaceuticals, down from $677000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $1.1 million in Q4 2022 to a low of -$3.8 million in Q4 2024.
  • A 5-year average of -$162650.0 and a median of -$181000.0 in 2021 define the central range for Tax Provisions.
  • Biggest YoY gain for Tax Provisions was 3557.14% in 2021; the steepest drop was 6700.0% in 2021.
  • Xenon Pharmaceuticals' Tax Provisions stood at $484000.0 in 2021, then soared by 135.33% to $1.1 million in 2022, then plummeted by 118.0% to -$205000.0 in 2023, then crashed by 1777.07% to -$3.8 million in 2024, then skyrocketed by 113.98% to $538000.0 in 2025.
  • Per Business Quant, the three most recent readings for XENE's Tax Provisions are $538000.0 (Q4 2025), $677000.0 (Q3 2025), and -$626000.0 (Q2 2025).